EMD Serono has new president; Endocyte boosted by prospects of ovarian cancer therapy;

@FierceBiotech: J&J's success with Hep C partners might hit a snag. Story | Follow @FierceBiotech

> Impax Pharmaceuticals, division of Impax Laboratories ($IPXL), says that it has received $400,000 from The Michael J. Fox Foundation to continue developing IPX066, an extended release carbidopa-levodopa for patients with Parkinson's disease. Release

> Seeking Alpha has a story about how cancer drug developer Endocyte ($ECYT) has made strides with its stock price since its IPO in February, boosted by the prospects of its experimental treatment for advanced ovarian cancer. Report

> Inovio Pharmaceuticals ($INO) said today that it has seen "significant" immune responses in an initial clinical trial of its DNA vaccine called VGX-3400X for avian H5N1 influenza. Item

> James Hoyes has been named president of EMD Serono, the U.S. affiliate of German pharmaceutical maker Merck KGaA. He will also be a member of the executive management board of Merck Serono. Announcement

> Regeneron ($REGN) financial chief Murray Goldberg told Xconomy's Arlene Weintraub that collaborations with companies like French drug giant Sanofi ($SNY) have put the company in the "top tier" in drug R&D. Article

@FiercePharma: Note to Pfizer: Bayer shopping for vet buys. Article | Follow @FiercePharma

> Merck job cuts set to accelerate. Item

> Expect more pharma M&A, less pharma hiring. Report

> Yervoy may help BMS survive European squeeze. More

> FDA taps Dartmouth ex-dean for new post. Story

> French minister overhauls pharma regs. Article

Manufacturing News

> Indian pharmas seek to protect their edge Report

> Corpedia, Second City bring comedy to compliance training. Item

> Hamburg appoints FDA deputies; Spielberg oversees drugs. Report

> GSK's Witty: West can compete in manufacturing. Story

> Pew track/trace call highlights congressional dallying. News

> Expert: Boost audit programs to keep up with outsourcing More

Vaccines News

> With Gates Foundation backing, Liquidia advances novel flu vaccine. Item

> Shingles vaccination levels fall short of expectations. Report

> Crucell and Scripps find antibody for universal flu vax. News

> The CIA, bin Laden and the future of vaccine programs. Story

> GSK gets Boostrix approval for adults over 65. Article

> Microneedles may be better for H1N1 delivery. More

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.